Clodronate for Bone Pain Relief in Prostate Cancer
Author Information
Author(s): T Kylmala, T Taube, TLJ Tammela, L Risteli, J Risteli, I Elomaa
Primary Institution: Tampere University Hospital, University of Helsinki, University of Oulu
Hypothesis
Does combined intravenous and oral administration of clodronate provide better pain relief than oral administration alone in patients with prostate cancer?
Conclusion
The study found that clodronate treatment provided only a modest improvement in pain relief compared to placebo.
Supporting Evidence
- Pain relief was only about 10% better in the clodronate group than in the placebo group.
- Performance status was better in the clodronate group at various time points.
- Statistical significance was observed in performance status at admission and at 1 and 12 months.
Takeaway
Doctors wanted to see if giving clodronate through an IV and by mouth would help men with prostate cancer feel less pain, but it only helped a little bit more than not taking it at all.
Methodology
The study was a double-blind, placebo-controlled trial involving 57 patients with advanced prostate cancer who were treated with clodronate or placebo.
Potential Biases
Potential bias due to the subjective nature of pain assessment.
Limitations
The study had a small sample size and the pain relief was only modest.
Participant Demographics
Patients were men with advanced prostate cancer, with a mean age of 72 years.
Statistical Information
P-Value
p=0.055
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website